Background: Neoadjuvant immunotherapy, particularly immune checkpoint inhibitors (ICIs), has emerged as a promising therapeutic strategy in the treatment of Triple-Negative breast cancer (TNBC). This systematic review evaluates the clinical impact of ICIs in combination with neoadjuvant chemotherapy, focusing on their improving pathological complete response (pCR) rates and outcomes. This review was conducted using PRISMA guidelines. A comprehensive literature search was conducted across multiple databases, including PubMed, Google Scholar, and EMBASE, for studies evaluating the use of ICIs in neoadjuvant therapy regimens for early-stage TNBC. Overall, while neoadjuvant ICIs represent a potential breakthrough in TNBC treatment, further clinical trials and long-term data are necessary to better define their role in improving patient outcomes.
References
[1]
Foulkes, W.D., Smith, I.E. and Reis-Filho, J.S. (2010) Triple-Negative Breast Cancer. New England Journal of Medicine, 363, 1938-1948. https://doi.org/10.1056/nejmra1001389
[2]
Tian, Q., Du, P., Li, S., Bai, Z., Yang, Y. and Zeng, J. (2017) Effect of Antitumor Treatments on Triple-Negative Breast Cancer Patients. Medicine, 96, e8389. https://doi.org/10.1097/md.0000000000008389
[3]
Schmid, P., Rugo, H.S., Adams, S., Schneeweiss, A., Barrios, C.H., Iwata, H., et al. (2020) Atezolizumab Plus Nab-Paclitaxel as First-Line Treatment for Unresectable, Locally Advanced or Metastatic Triple-Negative Breast Cancer (Impassion130): Updated Efficacy Results from a Randomised, Double-Blind, Placebo-Controlled, Phase 3 Trial. The Lancet Oncology, 21, 44-59. https://doi.org/10.1016/s1470-2045(19)30689-8
[4]
Cortes, J., Cescon, D.W., Rugo, H.S., et al. (2020) Pembrolizumab Plus Chemotherapy versus Placebo Plus Chemotherapy for Previously Untreated Locally Recurrent Inoperable or Metastatic Triple-Negative Breast Cancer (KEYNOTE-355): A Randomized, Placebo-Controlled, Double-Blind, Phase 3 Clinical Trial. The Lancet, 396, 1817-1828.
[5]
Schmid, P., Adams, S., Rugo, H.S., Schneeweiss, A., Barrios, C.H., Iwata, H., et al. (2018) Atezolizumab and Nab-Paclitaxel in Advanced Triple-Negative Breast Cancer. New England Journal of Medicine, 379, 2108-2121. https://doi.org/10.1056/nejmoa1809615
[6]
Loibl, S., Untch, M., Burchardi, N., et al. (2019) A Randomised Phase II Study Investigating Durvalumab in Addition to an Anthracycline Taxane-Based Neoadjuvant Therapy in Early Triple-Negative Breast Cancer: Clinical Results and Biomarker Analysis of Geparnuevo Study. Annals of Oncology, 30, 1279-1288. https://doi.org/10.1093/annonc/mdz158
[7]
Schmid, P., Cortes, J., Pusztai, L., McArthur, H., Kümmel, S., Bergh, J., et al. (2020) Pembrolizumab for Early Triple-Negative Breast Cancer. New England Journal of Medicine, 382, 810-821. https://doi.org/10.1056/nejmoa1910549
[8]
Nanda, R., Liu, M.C., Yau, C., Shatsky, R., Pusztai, L., Wallace, A., et al. (2020) Effect of Pembrolizumab Plus Neoadjuvant Chemotherapy on Pathologic Complete Response in Women with Early-Stage Breast Cancer. JAMA Oncology, 6, 676-684. https://doi.org/10.1001/jamaoncol.2019.6650
[9]
Mittendorf, E.A., Zhang, H., Barrios, C.H., Saji, S., Jung, K.H., Hegg, R., et al. (2020) Neoadjuvant Atezolizumab in Combination with Sequential Nab-Paclitaxel and Anthracycline-Based Chemotherapy versus Placebo and Chemotherapy in Patients with Early-Stage Triple-Negative Breast Cancer (Impassion031): A Randomized, Double-Blind, Phase 3 Trial. The Lancet, 396, 1090-1100. https://doi.org/10.1016/s0140-6736(20)31953-x
[10]
Gianni, L., Huang, C., Egle, D., Bermejo, B., Zamagni, C., Thill, M., et al. (2020) Abstract GS3-04: Pathologic Complete Response (pCR) to Neoadjuvant Treatment with or without Atezolizumab in Triple Negative, Early High-Risk and Locally Advanced Breast Cancer. Neotripapdl1 Michelangelo Randomized Study. Cancer Research, 80, GS3-04. https://doi.org/10.1158/1538-7445.sabcs19-gs3-04
[11]
Ademuyiwa, F.O., Gao, F., Chen, I., Northfelt, D.W., Wesolowski, R., Arora, M., et al. (2021) Abstract PD14-09: Nci 10013—A Randomized Phase 2 Study of Neoadjuvant Carboplatin and Paclitaxel, with or without Atezolizumab in Triple Negative Breast Cancer (tnbc). Cancer Research, 81, PD14-09. https://doi.org/10.1158/1538-7445.sabcs20-pd14-09
[12]
Lyons, T.G. (2019) Targeted Therapies for Triple-Negative Breast Cancer. Current Treatment Options in Oncology, 20, Article No. 82. https://doi.org/10.1007/s11864-019-0682-x
[13]
Hutchinson, K.E., Yost, S.E., Chang, C., Johnson, R.M., Carr, A.R., McAdam, P.R., etal. (2020) Comprehensive Profiling of Poor-Risk Paired Primary and Recurrent Triple-Negative Breast Cancers Reveals Immune Phenotype Shifts. Clinical Cancer Research, 26, 657-668. https://doi.org/10.1158/1078-0432.ccr-19-1773
[14]
Szekely, B., Bossuyt, V., Li, X., Wali, V.B., Patwardhan, G.A., Frederick, C., et al. (2018) Immunological Differences between Primary and Metastatic Breast Cancer. Annals of Oncology, 29, 2232-2239. https://doi.org/10.1093/annonc/mdy399
[15]
Pardoll, D.M. (2012) The Blockade of Immune Checkpoints in Cancer Immunotherapy. Nature Reviews Cancer, 12, 252-264. https://doi.org/10.1038/nrc3239
[16]
Keir, M.E., Butte, M.J., Freeman, G.J. and Sharpe, A.H. (2008) PD-1 and Its Ligands in Tolerance and Immunity. Annual Review of Immunology, 26, 677-704. https://doi.org/10.1146/annurev.immunol.26.021607.090331
[17]
Nishimura, H., Agata, Y., Kawasaki, A., Sato, M., Imamura, S., Minato, N., et al. (1996) Developmentally Regulated Expression of the PD-1 Protein on the Surface of Double-Negative (CD4–CD8–) Thymocytes. International Immunology, 8, 773-780. https://doi.org/10.1093/intimm/8.5.773
[18]
Topalian, S.L., Drake, C.G. and Pardoll, D.M. (2012) Targeting the PD-1/B7-H1(PD-L1) Pathway to Activate Anti-Tumor Immunity. Current Opinion in Immunology, 24, 207-212. https://doi.org/10.1016/j.coi.2011.12.009
[19]
Taube, J.M., Anders, R.A., Young, G.D., Xu, H., Sharma, R., McMiller, T.L., et al. (2012) Colocalization of Inflammatory Response with B7-H1 Expression in Human Melanocytic Lesions Supports an Adaptive Resistance Mechanism of Immune Escape. Science Translational Medicine, 4, 127ra37. https://doi.org/10.1126/scitranslmed.3003689
[20]
Mittendorf, E.A., Philips, A.V., Meric-Bernstam, F., Qiao, N., Wu, Y., Harrington, S., et al. (2014) PD-L1 Expression in Triple-Negative Breast Cancer. Cancer Immunology Research, 2, 361-370. https://doi.org/10.1158/2326-6066.cir-13-0127
[21]
Narayan, P., Wahby, S., Gao, J.J., Amiri-Kordestani, L., Ibrahim, A., Bloomquist, E., et al. (2020) FDA Approval Summary: Atezolizumab Plus Paclitaxel Protein-Bound for the Treatment of Patients with Advanced or Metastatic TNBC Whose Tumors Express Pd-l1. Clinical Cancer Research, 26, 2284-2289. https://doi.org/10.1158/1078-0432.ccr-19-3545
[22]
Budd, G.T., Barlow, W.E., Moore, H.C.F., Hobday, T.J., Stewart, J.A., Isaacs, C., et al. (2015) SWOG S0221: A Phase III Trial Comparing Chemotherapy Schedules in High-Risk Early-Stage Breast Cancer. Journal of Clinical Oncology, 33, 58-64. https://doi.org/10.1200/jco.2014.56.3296
[23]
Gianni, L., Huang, C.S., Egle, D., Bermejo, B., Zamagni, C., Thill, M., et al. (2022) Pathologic Complete Response (PCR) to Neoadjuvant Treatment with or without Atezolizumab in Triple-Negative, Early High-Risk and Locally Advanced Breast Cancer: Neotrip Michelangelo Randomized Study. Annals of Oncology, 33, 534-543. https://doi.org/10.1016/j.annonc.2022.02.004
[24]
Loibl, S., Schneeweiss, A., Huober, J., Braun, M., et al. (2022) Neoadjuvant Durvalumab Improves Survival in Early Triple-Negative Breast Cancer Independent of Pathological Complete Response. Annals of Oncology, 33, 1149-1158. https://doi.org/10.1016/j.annonc.2022.07.1940
[25]
Won, K. and Spruck, C. (2020) Triplenegative Breast Cancer Therapy: Current and Future Perspectives (review). International Journal of Oncology, 57, 1245-1261. https://doi.org/10.3892/ijo.2020.5135
[26]
Mougalian, S.S., Soulos, P.R., Killelea, B.K., Lannin, D.R., Abu-Khalaf, M.M., DiGiovanna, M.P., et al. (2015) Use of Neoadjuvant Chemotherapy for Patients with Stage I to III Breast Cancer in the United States. Cancer, 121, 2544-2552. https://doi.org/10.1002/cncr.29348
[27]
Cortazar, P., Zhang, L., Untch, M., Mehta, K., Costantino, J.P., Wolmark, N., et al. (2014) Pathological Complete Response and Long-Term Clinical Benefit in Breast Cancer: The CTNeoBC Pooled Analysis. The Lancet, 384, 164-172. https://doi.org/10.1016/s0140-6736(13)62422-8
[28]
U.S. Department of Health and Human Services, Food and Drug Administration, Oncology Center of Excellence, CDER and CBER (2020) Pathological Complete Response in Neoadjuvant Treatment of High-Risk Early-Stage Breast Cancer: Use as an Endpoint to Support Accelerated Approval Guidance for Industry. https://www.fda.gov/media/83507/download
[29]
Patrinely, J.R., Johnson, R., Lawless, A.R., Bhave, P., Sawyers, A., Dimitrova, M., etal. (2021) Chronic Immune-Related Adverse Events Following Adjuvant Anti-PD-1 Therapy for High-Risk Resected Melanoma. JAMA Oncology, 7, 744-748. https://doi.org/10.1001/jamaoncol.2021.0051
[30]
Chen, C., Yu, H. and Yu, S. (2022) Cutaneous Adverse Events Associated with Immune Checkpoint Inhibitors: A Review Article. Current Oncology, 29, 2871-2886. https://doi.org/10.3390/curroncol29040234
[31]
Brahmer, J.R., Lacchetti, C., Schneider, B.J., Atkins, M.B., Brassil, K.J., Caterino, J.M., et al. (2018) Management of Immune-Related Adverse Events in Patients Treated with Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline. Journal of Clinical Oncology, 36, 1714-1768. https://doi.org/10.1200/jco.2017.77.6385
